American Home Products
Executive Summary
Maryland U.S. Attorney is investigating Wyeth-Ayerst's "adverse events reporting system and the reporting of adverse events related to Redux and Pondimin," AHP discloses in Securities & Exchange Commission filing. AHP "is in the process of responding to the subpoena and continues to believe that its conduct with respect to the diet drugs has at all times been lawful and appropriate"
You may also be interested in...
Wyeth DT Vaccine Seized By FDA; Manufacturing Upgrades Under Way
Wyeth-Ayerst has been working on process improvements at its Marietta, Penn. plant for six months, the company said following a June 15 seizure action filed by FDA against products produced at the facility.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011